AKT1 and gastric cancer: Wang et al. identified a novel lncRNA, cisplatin resistance-associated lncRNA (CRAL), which acts as a ceRNA to reverse CDDP resistance in GC via the miR-505/CYLD/AKT axis (Wang Z. et al., 2020).